Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who have atrial fibrillation, atrial flutter, or a blood clot condition (such as a clot in the leg or lungs), and who are taking a full-strength dose of one of these blood thinners: apixaban, dabigatran, edoxaban, or rivaroxaban (at specific doses suited to their age and kidney function)
- People considered higher risk for bleeding who are scheduled for a planned surgery with a high chance of bleeding, or any planned surgery that uses a type of anaesthesia injected near the spine or a nerve block in a deep area of the body
Who may not be able to join:
- People whose reason for taking a blood thinner is a blood clot in an unusual location, such as the bowel, brain, or arm
- People taking a lower-dose version of their blood thinner for long-term clot prevention (for example, rivaroxaban 10 mg daily or apixaban 2.5 mg twice daily used for this purpose), or another low-dose regimen
- People whose kidneys are not functioning well enough — the specific kidney function level that may exclude someone depends on which blood thinner is being taken (confirm with trial site)
- People with significant memory, thinking, or mental health difficulties that would make it hard to stay in reliable contact during the study follow-up period
- People who are not able or not willing to give their consent to participate
- People who have already taken part in a previous study called PAUSE 2
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: James Douketis, MD, McMaster University/St. Joseph's Healthcare
Phone: 905-522-1155
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients randomized to each study arm with a residual pre-operative DOAC level < 30 ng/mL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.